Metachronous gastric cancer after successful Helicobacter pylori eradication

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11552-11559

  Shiotani, Akiko ^a   Haruma, Ken ^a   Graham, David Y ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atrophic gastritis; Cancer prevention; Intestinal metaplasia; miRNA; Pepsinogen

Indexed keywords

MICRORNA; PEPSINOGEN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR CDX2; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER;

ATROPHIC GASTRITIS; ATTRIBUTABLE RISK; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIUM EXAMINATION; BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; ENDOSCOPIC THERAPY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS (TOPIC); METACHRONOUS GASTRIC CANCER; MULTICENTER STUDY (TOPIC); NONHUMAN; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STOMACH CANCER; STOMACH LESION; BLOOD; DRUG EFFECTS; GASTRECTOMY; HELICOBACTER INFECTIONS; INCIDENCE; JAPAN; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SECOND CANCER; STOMACH NEOPLASMS; TIME; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; GASTRECTOMY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; JAPAN; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84909636259     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11552     Document Type: Review

References (69)

1. Melton SD, Genta RM, Souza RF. Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol 2010; 7: 620-628 [PMID: 20924366 DOI: 10.1038/nrgastro.2010.153]
2. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659-672 [PMID: 17681184 DOI: 10.1053/j.gastro.2007.06.026]
3. Fukao A, Tsubono Y, Tsuji I, HIsamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995; 60: 45-48 [PMID: 7814150]
4. Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 2006; 41: 929-942 [PMID: 17096062 DOI: 10.1007/s00535-006-1954-3]
5. Ma CJ, Sun LC, Chen FM, Lu CY, Shih YL, Tsai HL, Chuang JF, Wang JY. A double-blind randomized study comparing the efficacy and safety of a composite vs a conventional intravenous fat emulsion in postsurgical gastrointestinal tumor patients. Nutr Clin Pract 2012; 27: 410-415 [PMID: 22460385 DOI: 10.1177/0884533611436115]
6. Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005; 54: 735-738 [PMID: 15888771 DOI: 10.1136/gut.2004.056549]
7. Shiotani A, Cen P, Graham DY. Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 2013; 23: 492-501 [PMID: 23876852 DOI: 10.1016/j.semcancer.2013.07.004]
8. Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy 2005; 37: 990-993 [PMID: 16189772 DOI: 10.1055/s-2005-870198]
9. Takeda J, Toyonaga A, Koufuji K, Kodama I, Aoyagi K, Ohta J, Aoyama Y, Hata H. Resected early gastric cancer - clinicopathological studies on 610 cases. Kurume Med J 1995; 42: 87-94 [PMID: 7564169]
10. Miyoshi E, Haruma K, Hiyama T, Tanaka S, Yoshihara M, Shimamoto F, Chayama K. Microsatellite instability is a genetic marker for the development of multiple gastric cancers. Int J Cancer 2001; 95: 350-353 [PMID: 11668515]
11. Uedo N, Fujishiro M, Goda K, Hirasawa D, Kawahara Y, Lee JH, Miyahara R, Morita Y, Singh R, Takeuchi M, Wang S, Yao T. Role of narrow band imaging for diagnosis of early-stage esophagogastric cancer: current consensus of experienced endoscopists in Asia-Pacific region. Dig Endosc 2011; 23 Suppl 1: 58-71 [PMID: 21535204 DOI: 10.1111/j.1443-1661.2011.01119.x]
12. Shiotani A, Uedo N, Iishi H, Yoshiyuki Y, Ishii M, Manabe N, Kamada T, Kusunoki H, Hata J, Haruma K. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion 2008; 78: 113-119 [PMID: 19023205 DOI: 10.1159/000173719]
13. Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, Ohnita K, Mizuta Y, Shiozawa J, Kohno S. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut 2009; 58: 331-336 [PMID: 19001058 DOI: 10.1136/gut.2008.165381]
14. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397 [PMID: 18675689 DOI: 10.1016/S0140-6736(08)61159-9]
15. Nyrén O . Is Helicobacter pylori really the cause of gastric cancer? Semin Cancer Biol 1998; 8: 275-283 [PMID: 9870034]
16. El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002; 94: 1428-1436 [PMID: 11920498]
17. Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, Tatematsu M, Sugisaki Y, Naito Z, Tajiri T. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007; 98: 790-794 [PMID: 17470129 DOI: 10.1111/j.1349-7006.2007.00478.x]
18. Nakayama Y, Graham DY. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther 2004; 2: 599-610 [PMID: 15482223]
19. Satoh K, Kimura K, Taniguchi Y, Yoshida Y, Kihira K, Takimoto T, Kawata H, Saifuku K, Ido K, Takemoto T, Ota Y, Tada M, Karita M, Sakaki N, Hoshihara Y. Distribution of inflammation and atrophy in the stomach of Helicobacter pylori-positive and -negative patients with chronic gastritis. Am J Gastroenterol 1996; 91: 963-969 [PMID: 8633589]
20. Kimura K . Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. Gastroenterology 1972; 63: 584-592 [PMID: 5077145]
21. Shiotani A, Iishi H, Uedo N, Ishiguro S, Tatsuta M, Nakae Y, Kumamoto M, Merchant JL. Evidence that loss of sonic hedgehog is an indicator of Helicobater pylori-induced atrophic gastritis progressing to gastric cancer. Am J Gastroenterol 2005; 100: 581-587 [PMID: 15743355 DOI: 10.1111/j.1572-0241.2005.41001.x]
22. Shiotani A, Uedo N, Iishi H, Tatsuta M, Ishiguro S, Nakae Y, Kamada T, Haruma K, Merchant JL. Re-expression of sonic hedgehog and reduction of CDX2 after Helicobacter pylori eradication prior to incomplete intestinal metaplasia. Int J Cancer 2007; 121: 1182-1189 [PMID: 17520681 DOI: 10.1002/ijc.22835]
23. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD, Kaestner KH. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002; 122: 689-696 [PMID: 11875002]
24. Nomura S, Baxter T, Yamaguchi H, Leys C, Vartapetian AB, Fox JG, Lee JR, Wang TC, Goldenring JR. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felisinfected mice. Gastroenterology 2004; 127: 582-594 [PMID: 15300590]
25. Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, Konieczny SF, Nomura S, Goldenring JR. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 2008; 134: 511-522 [PMID: 18242217 DOI: 10.1053/j.gastro.2007.11.058]
26. Weis VG, Goldenring JR. Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 2009; 12: 189-197 [PMID: 20047123 DOI: 10.1007/s10120-009-0527-6]
27. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 2005; 128: 1567-1578 [PMID: 15887152]
28. Shiotani A, Iishi H, Uedo N, Kumamoto M, Nakae Y, Ishiguro S, Tatsuta M, Graham DY. Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer 2005; 115: 463-469 [PMID: 15688378 DOI: 10.1002/ijc.20852]
29. Varon C, Dubus P, Mazurier F, Asencio C, Chambonnier L, Ferrand J, Giese A, Senant-Dugot N, Carlotti M, Mégraud F. Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology 2012; 142: 281-291 [PMID: 22062361 DOI: 10.1053/j.gastro.2011.10.036]
30. Weis VG, Sousa JF, LaFleur BJ, Nam KT, Weis JA, Finke PE, Ameen NA, Fox JG, Goldenring JR. Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression. Gut 2013; 62: 1270-1279 [PMID: 22773549 DOI: 10.1136/gutjnl-2012-302401]
31. Nam KT, O'Neal RL, Coffey RJ, Finke PE, Barker N, Goldenring JR. Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Gut 2012; 61: 1678-1685 [PMID: 22198711 DOI: 10.1136/gutjnl-2011-301193]
32. Goldenring JR, Nam KT. Oxyntic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci 2010; 96: 117-131 [PMID: 21075342 DOI: 10.1016/B978-0-12-381280-3.00005-1]
33. Tsai YC, Hsiao WH, Yang HB, Cheng HC, Chang WL, Lu CC, Sheu BS. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther 2013; 37: 969-978 [PMID: 23550594 DOI: 10.1111/apt.12291]
34. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
35. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-697 [PMID: 10205207]
36. Kudo T, Kakizaki S, Sohara N, Onozato Y, Okamura S, Inui Y, Mori M. Analysis of ABC (D) stratification for screening patients with gastric cancer. World J Gastroenterol 2011; 17: 4793-4798 [PMID: 22147980 DOI: 10.3748/wjg.v17.i43.4793]
37. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method". Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 405-414 [PMID: 21785258]
38. Samloff IM. Pepsinogens, pepsins, and pepsin inhibitors. Gastroenterology 1971; 60: 586-604 [PMID: 4324336]
39. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971; 61: 185-188 [PMID: 4935210]
40. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006; 9: 245-253 [PMID: 17235625 DOI: 10.1007/s10120-006-0397-0]
41. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004; 109: 138-143 [PMID: 14735480 DOI: 10.1002/ijc.11680]
42. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-768 [PMID: 15888780 DOI: 10.1136/gut.2004.055400]
43. Kawai T, Miki K, Ichinose M, Kenji Y, Miyazaki I, Kawakami K, Kataoka M, Yamagishi T, Sofuni A, Itoi T, Moriyasu F, Takagi Y, Aoki T, Matsubayashi J, Mukai K. Changes in evaluation of the pepsinogen test result following Helicobacter pylori eradication therapy in Japan. Inflammopharmacology 2007; 15: 31-35 [PMID: 17323193 DOI: 10.1007/s10787-006-0009-y]
44. Kaise M, Miwa J, Fujimoto A, Tashiro J, Tagami D, Sano H, Ohmoto Y. Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker. Gastric Cancer 2013; 16: 329-337 [PMID: 22907485 DOI: 10.1007/s10120-012-0185-y]
45. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838 [PMID: 15944708]
46. Wang J, Wang Q, Liu H, Hu B, Zhou W, Cheng Y. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett 2010; 297: 137-143 [PMID: 20797817]
47. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008; 3: e3694 [PMID: 19002258 DOI: 10.1371/journal.pone.0003694]
48. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518 [PMID: 18663219 DOI: 10.1073/pnas.0804549105]
49. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675 [PMID: 18318758 DOI: 10.1111/j.1365-2141.2008.07077.x]
50. Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C, Wang C, Ren Z, Zhao Y, Wu S, Zhuang R, Zhang Y, Hu H, Liu C, Xu L, Wang J, Shen H, Zhang J, Zen K, Zhang CY. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012; 130: 1620-1628 [PMID: 21557218 DOI: 10.1002/ijc.26177]
51. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381 [PMID: 19201770 DOI: 10.1136/gut.2008.167817]
52. Shiotani A, Murao T, Kimura Y, Matsumoto H, Kamada T, Kusunoki H, Inoue K, Uedo N, Iishi H, Haruma K. Identification of serum miRNAs as novel non-invasive biomarkers for detection of high risk for early gastric cancer. Br J Cancer 2013; 109: 2323-2330 [PMID: 24104965 DOI: 10.1038/bjc.2013.596]
53. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol 2010; 45: 1-8 [PMID: 19714291 DOI: 10.1007/s00535-009-0117-8]
54. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol 2007; 42 Suppl 17: 21-27 [PMID: 17238021 DOI: 10.1007/s00535-006-1924-9]
55. Take S, Mizuno M, Ishiki K, Yoshida T, Ohara N, Yokota K, Oguma K, Okada H, Yamamoto K. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011; 46: 318-324 [PMID: 21103997 DOI: 10.1007/s00535-010-0347-9]
56. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, Liu WD, Hu Y, Han ZX, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, You WC, Gail MH. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104: 488-492 [PMID: 22271764 DOI: 10.1093/jnci/djs003]
57. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-128 [PMID: 19620164]
58. Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C, Enomoto S, Inoue I, Iguchi M, Maekita T, Ueda K, Utsunomiya H, Tamai H, Fujishiro M, Iwane M, Takeshita T, Mohara O, Ichinose M. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009; 125: 2697-2703 [PMID: 19610064 DOI: 10.1002/ijc.24591]
59. Shiotani A, Murao T, Uedo N, Iishi H, Yamanaka Y, Kamada T, Kusunoki H, Inoue K, Haruma K. Eradication of H. pylori did not improve abnormal sonic hedgehog expression in the high risk group for gastric cancer. Dig Dis Sci 2012; 57: 643-649 [PMID: 21953141 DOI: 10.1007/s10620-011-1916-3]
60. Shiotani A, Uedo N, Iishi H, Murao T, Kanzaki T, Kimura Y, Kamada T, Kusunoki H, Inoue K, Haruma K. H. pylori eradication did not improve dysregulation of specific oncogenic miRNAs in intestinal metaplastic glands. J Gastroenterol 2012; 47: 988-998 [PMID: 22382634 DOI: 10.1007/s00535-012-0562-7]
61. Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go? Dig Dis 2012; 30: 268-276 [PMID: 22722551 DOI: 10.1159/000336990]
62. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-642 [PMID: 9264278]
63. Maehata Y, Nakamura S, Fujisawa K, Esaki M, Moriyama T, Asano K, Fuyuno Y, Yamaguchi K, Egashira I, Kim H, Kanda M, Hirahashi M, Matsumoto T. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012; 75: 39-46 [PMID: 22018552 DOI: 10.1016/j.gie.2011.08.030]
64. Kato M, Nishida T, Yamamoto K, Hayashi S, Kitamura S, Yabuta T, Yoshio T, Nakamura T, Komori M, Kawai N, Nishihara A, Nakanishi F, Nakahara M, Ogiyama H, Kinoshita K, Yamada T, Iijima H, Tsujii M, Takehara T. Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer: a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013; 62: 1425-1432 [PMID: 22914298 DOI: 10.1136/gutjnl-2011-301647]
65. Seo JY, Lee DH, Cho Y, Lee DH, Oh HS, Jo HJ, Shin CM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N, Jung HC, Song IS. Eradication of Helicobacter pylori reduces metachronous gastric cancer after endoscopic resection of early gastric cancer. Hepatogastroenterology 2013; 60: 776-780 [PMID: 23165228 DOI: 10.5754/hge12929]
66. Hanaoka N, Uedo N, Shiotani A, Inoue T, Takeuchi Y, Higashino K, Ishihara R, Iishi H, Haruma K, Tatsuta M. Autofluorescence imaging for predicting development of metachronous gastric cancer after Helicobacter pylori eradication. J Gastroenterol Hepatol 2010; 25: 1844-1849 [PMID: 21091995 DOI: 10.1111/j.1440-1746.2010.06442.x]
67. Sakata K, Tamura G, Endoh Y, Ohmura K, Ogata S, Motoyama T. Hypermethylation of the hMLH1 gene promoter in solitary and multiple gastric cancers with microsatellite instability. Br J Cancer 2002; 86: 564-567 [PMID: 11870538 DOI: 10.1038/sj.bjc.6600076]
68. Fukuda M, Yokozaki H, Shiba M, Higuchi K, Arakawa T. Genetic and epigenetic markers to identify high risk patients for multiple early gastric cancers after treatment with endoscopic mucosal resection. J Clin Biochem Nutr 2007; 40: 203-209 [PMID: 18398497 DOI: 10.3164/jcbn.40.203]
69. Chon I, Choi C, Shin CM, Park YS, Kim N, Lee DH. Effect of Helicobacter pylori eradication on subsequent dysplasia development after endoscopic resection of gastric dysplasia. Korean J Gastroenterol 2013; 61: 307-312 [PMID: 23877210]